RxDoctor Payments Data

David Russell

Psychiatric/Mental Health · Stockton, CANPI 1477167666

Payments from drug & device makers

$2,418in general payments, 2019–2025

Across 72 payments — averaging $33.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Otsuka America Pharmaceutical, Inc.$772
  • Johnson & Johnson$687
  • Alkermes, Inc.$470
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$325
  • E.r. Squibb & Sons, L.L.C.$111
  • Indivior Inc.$55

What the payments were for

  • Food & beverage$2,37198%
  • Education$472%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,418 in reported general payments places this provider in the 80th percentile of 2,433 psychiatric/mental health providers in California.

See all psychiatric/mental health providers in California

Medicare billing

Part B allowed, 2024
$4,257
Medicare patients
14
Services billed
41

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega TrinzaPaliperidone Palmitate27$264,812
Abilify AsimtufiiAripiprazole40$198,868
Invega SustennaPaliperidone Palmitate59$192,989
Abilify MaintenaAripiprazole72$166,391
IngrezzaValbenazine Tosylate15$125,660
LybalviOlanzapine/Samidorphan Malate15$22,374
VraylarCariprazine Hcl18$11,364
Olanzapine OdtOlanzapine61$5,730
Risperidone OdtRisperidone23$3,829
Paliperidone ErPaliperidone13$1,763
Clozapine38$1,629
Olanzapine183$1,482
Divalproex Sodium106$991
Benztropine Mesylate158$711
Quetiapine Fumarate109$646

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Trinza, Invega Sustenna$687$457,80086 claims
Otsuka America Pharmaceutical, Inc.Abilify Asimtufii, Abilify Maintena$772$365,259112 claims
Alkermes, Inc.Lybalvi$470$22,37415 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,433 psychiatric/mental health providers in California.

Other psychiatric/mental health in Stockton

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →